4McArthur J G, Mulligan R C. Induction of protective antitumor imnmnity by gene-modifide dendritic cells[ J]. J Immunother, 1998 ;21:41-47.
5Schmidt-wolf I G, Negrin R S, Kiem H Pet al. Use of a SCID mouse/human lymphonra model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J]. J Exp Med, 1991 ; 174:139-149.
6Levin D, Constant S, Pasqualini T et al. Role of dendritic cells in the priming of CD^4+ T lymphocytes to peptide antigen in vivo[ J ]. J Immunol, 1993 ; 151 : 6742-6750.
7Thumher M, Papesh C, Ramoner R etal. In vitro generation of CD83^+ human blood dendritic cells for active tumor immunotherapy [ J ]. Exp Hematol, 1997; 25 : 232-237.
8Wolf I G H, Negrin R S, kiem H Pet al. Phenotypic characterization and identification of effecter cells involved in tumor cell recognition of cytokine induced killer cells[J]. Exp Hematol, 1993;21 : 1673-1679.
9Lu P H, Negrin R S. Anovel population of expanded human CD3^+ CD56^+ cells derived from T cells with potent in vivo antitumor activity in micewith sever combined immunodeficiency[ J]. J I mmunol, 1994; 153 : 1687-1696.
10Linn Y C,Hui K M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukia[ J ]. Leuk Lymphoma, 2003; 44: 1457-1462.
